Skip to content
Screener

Onto Innovation ONTO Business Segments — Merger And Acquisitions Related Expenses2

Similar metrics at other companies

Ginkgo Bioworks logo
DNAReportable Segment — Merger and acquisition related expense (income)
$1.11M+131%
Pacific Biosciences of California logo
PACBReportable Segment — Merger-related expenses
$0—
Norfolk Southern logo
NSCReportable Segment — Merger-related expenses
$51M—
Theravance Biopharma logo
TBPHSingle Reportable — Restructuring And Related Expenses
$3.63M—
Capricor Therapeutics logo
CAPRSingle Reportable — Labor And Related Expense
$2.23M+48.9%
LQD
LQDASingle Reportable — Labor And Related Expense
$31.65M+57.6%

Other financials

Income statement

See full
Revenue$343.1M+35.3%
Gross profit$183.3M+50.1%
Operating income$63.6M+97.1%
Net income$60.1M+75.8%
EPS (diluted)$1.21+75.4%

Balance sheet

See full
Cash & equivalents$1.3B+476%
Total debt$17.5M+15.3%
Total equity$1.9B-2.1%
Total assets$3.7B+72.8%

Cash flow

See full
Operating cash flow$61.5M+6.2%
CapEx$3.7M-73.4%
Free cash flow$57.9M+31.0%

Valuation

See full
Market cap$13.73B+212%
P/E84.6×+58.6×
P/S12.3×+8.0×

Profitability

See full
Gross margin50.4%-1.2pp
Operating margin12%-6.4pp
Net margin14.5%-1.8pp
FCF margin22.5%-0.5pp

Returns & leverage

See full
Return on equity8.3%-0.6pp
Debt / equity0×0.0×
Current ratio9.7×+0.1×

Where this comes from

Reported directly by Onto Innovation in its filing.

Tagged under the XBRL concept onto:MergerAndAcquisitionsRelatedExpenses2.

The source filing: Onto Innovation’s 10-K, filed February 24, 2026.

Filed
Feb 24, 2026, 4:04 PM EST
Fiscal year
FY2025
Accession
0001193125-26-066937
Line itemYear Ended / January 3,2026Year Ended / December 28,2024Year Ended / December 30,2023
Adjusted general and administrative (3)90,73676,68766,735
Other segment items:
Restructuring and other (4)63,38923,07710,599
Merger and acquisitions related (4)19,6017,6532,607
Litigation (4)—2711,337
Amortization39,40949,43754,823
Operating income132,927187,103116,078
Interest income, net34,97133,48920,356

Item 16. Form 10-K Summary.

FAQ

What is Onto Innovation's business segments — merger and acquisitions related expenses2?
Onto Innovation (ONTO) reported business segments — merger and acquisitions related expenses2 of $4.9M in Q4 2025.
How has Onto Innovation's business segments — merger and acquisitions related expenses2 changed year-over-year?
Onto Innovation's business segments — merger and acquisitions related expenses2 increased by 156.1% year-over-year, from $1.91M to $4.9M.
What is the long-term trend for Onto Innovation's business segments — merger and acquisitions related expenses2?
Over 3 years (2022 to 2025), Onto Innovation's business segments — merger and acquisitions related expenses2 has grown at a 50.4% compound annual growth rate (CAGR), from $5.76M to $19.6M.
What does business segments — merger and acquisitions related expenses2 mean?
Includes costs directly attributable to the integration of acquired businesses, such as legal, advisory, and transition fees. This metric helps investors isolate the impact of inorganic growth strategies on the company's financial results.

Ask your AI about Onto Innovation's business segments — merger and acquisitions related expenses2.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude